Proteon Therapeutics (PRTO) stock price, revenue, and financials

Proteon Therapeutics market cap is $18.5 m.
View Company

$18.5 M

PRTO Mkt cap, 09-Jan-2020
Proteon Therapeutics Net income (Q1, 2020)-10.1 M
Proteon Therapeutics EBIT (Q1, 2020)-10.2 M
Proteon Therapeutics Cash, 31-Mar-202036.1 M
Proteon Therapeutics EV-15.8 M
Get notified regarding key financial metrics and revenue changes at Proteon TherapeuticsLearn more
Banner background

Proteon Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

2.9m

R&D expense

6.4m12.4m18.9m21.7m11.8m6.4m

General and administrative expense

4.1m8.5m9.8m8.7m9.5m8.8m

Operating expense total

10.5m20.9m28.7m30.4m21.4m15.3m

EBIT

(7.6m)(20.9m)(28.7m)(30.4m)(21.4m)(15.3m)

EBIT margin, %

(257%)

Interest income

5.1m

Investment income

24.0k144.0k193.0k259.0k436.0k262.0k

Pre tax profit

(28.5m)(30.0m)(20.7m)(15.0m)

Income tax expense

(110.0k)

Net Income

(3.3m)(21.4m)(28.5m)(30.0m)(20.7m)(15.0m)

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

2.9m

R&D expense

1.8m2.6m3.1m3.1m4.3m5.2m4.8m4.2m3.9m10.3m4.1m2.8m2.4m4.0m2.1m206.0k3.1m

General and administrative expense

1.0m2.0m1.9m2.0m2.5m2.6m2.3m2.2m2.1m2.0m2.3m2.2m2.3m2.6m3.3m1.4m7.1m

Operating expense total

2.8m4.6m5.0m5.1m6.8m7.9m7.2m6.5m6.0m12.3m6.4m5.0m4.6m6.6m5.4m1.6m10.2m

Depreciation and amortization

32.0k

EBIT

134.0k(4.6m)(5.0m)(5.1m)(6.8m)(7.9m)(7.2m)(6.5m)(6.0m)(12.3m)(6.4m)(5.0m)(4.6m)(6.6m)(5.4m)(1.6m)(10.2m)

EBIT margin, %

5%

Investment income

40.0k37.0k34.0k56.0k53.0k46.0k32.0k46.0k83.0k92.0k106.0k113.0k105.0k73.0k53.0k

Income tax expense

Net Income

(5.2m)(4.6m)(5.1m)(5.4m)(6.6m)(7.9m)(7.1m)(6.5m)(5.6m)(12.3m)(6.1m)(4.9m)(4.5m)(6.5m)(5.3m)(1.5m)(10.1m)

Proteon Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

68.8m40.0m36.4m21.2m19.4m6.2m

Accounts Receivable

1.7b

Prepaid Expenses

1.0m1.3m1.3m1.4m744.0k

Current Assets

84.6m66.6m42.8m43.5m23.2m7.0m

PP&E

83.0k224.0k372.0k259.0k263.0k

Total Assets

84.8m67.5m43.5m44.0m23.5m7.0m

Accounts Payable

917.0k1.0m556.0k291.0k441.0k263.0k

Current Liabilities

2.3m4.1m5.1m9.2m3.1m583.0k

Total Liabilities

2.3m4.1m5.1m9.2m3.1m583.0k

Common Stock

16.0k16.0k18.0k19.0k557.6k

Preferred Stock

Additional Paid-in Capital

192.3m194.7m198.2m203.0m209.4m213.4m

Retained Earnings

(109.9m)(131.3m)(159.8m)(189.7m)(210.5m)(225.5m)

Total Equity

82.5m63.4m38.4m34.7m20.4m6.4m

Financial Leverage

1 x1.1 x1.1 x1.3 x1.2 x1.1 x

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

3.2m9.8m16.8m36.0m24.1m34.2m26.7m34.1m18.4m20.0m25.4m12.5m18.2m16.8m10.8m9.3m36.1m

Prepaid Expenses

168.0k1.2m1.1m829.0k1.1m1.2m1.7m1.3m1.3m554.0k1.2m1.1m871.0k1.0m614.0k277.0k3.6m

Current Assets

21.9m80.7m75.8m71.4m60.4m54.9m48.7m35.4m33.0m48.0m38.0m27.5m27.1m17.9m11.5m9.6m39.7m

PP&E

86.0k80.0k102.0k221.0k208.0k374.0k396.0k338.0k309.0k280.0k236.0k219.0k200.0k105.0k83.0k655.8k

Goodwill

29.4m

Total Assets

24.2m80.9m76.6m72.3m61.3m55.7m49.4m36.0m33.6m48.6m38.5m27.9m27.4m18.1m11.6m9.6m70.1m

Accounts Payable

1.0m1.2m502.0k591.0k431.0k527.0k591.0k474.0k1.2m226.0k7.0m431.0k385.0k1.7m60.0k394.0k2.6m

Short-term debt

135.0k68.0k1.3m

Current Liabilities

2.7m2.6m2.8m3.2m3.6m4.7m4.9m3.0m4.1m9.1m9.0m2.2m2.5m3.4m2.1m1.6m5.0m

Long-term debt

68.0k386.5k

Total Debt

135.0k136.0k1.7m

Total Liabilities

14.6m2.6m2.8m3.3m3.6m4.7m4.9m3.0m4.1m9.1m9.0m2.2m2.5m3.4m2.1m1.6m5.4m

Common Stock

16.0k16.0k16.0k16.0k16.0k17.0k17.0k18.0k18.0k18.0k18.0k19.0k19.0k19.0k19.0k5.8k

Preferred Stock

35.4m4.0

Additional Paid-in Capital

192.7m193.3m193.9m195.5m196.6m197.3m199.3m201.4m202.1m203.8m204.8m208.5m210.5m210.6m210.7m87.6m

Retained Earnings

(116.5m)(114.5m)(119.5m)(124.9m)(137.8m)(145.7m)(152.8m)(166.3m)(171.9m)(184.2m)(195.8m)(200.7m)(205.2m)(217.0m)(222.3m)(223.9m)(22.8m)

Total Equity

(116.6m)78.3m73.8m69.0m57.8m50.9m44.5m33.0m29.5m39.5m29.5m25.6m24.9m14.7m9.5m8.0m64.7m

Financial Leverage

-0.2 x1 x1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1.3 x1.1 x1.1 x1.2 x1.2 x1.2 x1.1 x

Proteon Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.3m)(21.4m)(28.5m)(30.0m)(20.7m)(15.0m)

Depreciation and Amortization

30.0k57.0k123.0k148.0k115.0k279.0k

Accounts Receivable

(32.0k)(26.0k)(46.0k)49.0k17.0k

Accounts Payable

955.0k1.3m1.1m4.2m(6.2m)(2.5m)

Cash From Operating Activities

(10.0m)(17.6m)(23.7m)(22.4m)(23.2m)(15.6m)

Purchases of PP&E

(51.0k)(198.0k)(271.0k)(35.0k)(119.0k)(16.0k)

Cash From Investing Activities

(12.5m)(11.3m)19.9m(16.1m)18.4m2.5m

Dividends Paid

Cash From Financing Activities

88.5m163.0k208.0k23.0m3.0m

Net Change in Cash

66.0m(28.8m)(3.6m)(15.2m)(1.8m)(13.2m)

Quarterly

USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(10.6m)(4.6m)(9.7m)(15.0m)(6.6m)(14.5m)(21.6m)(6.5m)(12.1m)(24.4m)(6.1m)(11.0m)(15.5m)(6.5m)(11.8m)(13.4m)(10.1m)

Depreciation and Amortization

21.0k8.0k17.0k33.0k24.0k52.0k87.0k40.0k77.0k115.0k32.0k61.0k83.0k174.0k196.0k279.0k49.8k

Accounts Receivable

(13.0k)(305.0k)(198.0k)(214.0k)(26.0k)(26.0k)46.0k(15.0k)(12.0k)(73.0k)4.0k(3.0k)(15.0k)5.0k10.0k

Accounts Payable

1.3m296.0k366.0k488.0k(367.0k)730.0k869.0k(2.1m)(942.0k)4.0m(220.0k)(7.0m)(6.7m)155.0k(1.0m)(1.5m)1.9m

Cash From Operating Activities

(7.9m)(3.9m)(8.5m)(12.4m)(5.9m)(11.5m)(18.1m)(7.4m)(10.7m)(16.7m)(5.5m)(15.8m)(18.9m)(5.1m)(11.0m)(12.5m)(7.1m)

Purchases of PP&E

(45.0k)(5.0k)(36.0k)(171.0k)(8.0k)(202.0k)(259.0k)(6.0k)(14.0k)(23.0k)(9.0k)(21.0k)(24.0k)(16.0k)(16.0k)(16.0k)(247.0k)

Cash From Investing Activities

(16.2m)(55.2m)(43.6m)(20.5m)(10.1m)5.5m4.6m4.9m(8.5m)(22.5m)9.5m7.0m13.0m2.5m2.5m2.5m3.5m

Short-term Borrowings

(370.8k)

Cash From Financing Activities

24.5m59.0k101.0k12.0k144.0k161.0k213.0k1.5m23.0m84.0k2.9m39.2m

Net Change in Cash

446.0k(59.1m)(52.0m)(32.9m)(16.0m)(5.8m)(13.4m)(2.3m)(18.0m)(16.4m)4.2m(8.7m)(2.9m)(2.6m)(8.6m)(10.0m)35.6m

Interest Paid

7.5k

Proteon Therapeutics Ratios

USDQ3, 2014

Financial Leverage

-0.2 x
View Proteon Therapeutics profile

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Learn more